Gilead Reports the Initiation of Two P-III Studies of Remdesivir to Treat COVID-19

 Gilead Reports the Initiation of Two P-III Studies of Remdesivir to Treat COVID-19

Gilead Reports the Initiation of Two P-III Studies of Remdesivir to Treat COVID-19

Shots:

  • The studies will evaluate 5-day and a 10-day dosing regimen of remdesivir (IV). One study will assess remdesivir + SOC in ~400 patients in a ratio (1:1) with sev. clinical manifestations of COVID-19 while the second study will assess remdesivir vs SOC as monothx. in ~600 patients in a ratio (1:1:1) with mod. clinical manifestations of the disease
  • The initiation follows the US FDA rapid review & acceptance of Gilead’s IND filing for remdesivir to treat COVID-19. The studies will expand the ongoing research of the therapy which include clinical trials in China’s Hubei province and the US
  • Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro/ vivo in animal models against viral pathogens including Ebola, Marburg, MERS and SARS

Click here ­to­ read full press release/ article | Ref: Gilead  | Image: NY Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post